SERPINA1 and liver disorder: Whether this also applies to people carrying a Pi*Z allele is unknown, but since the FIB‐4 and APRI appear to exhibit a reasonable balance between discriminative utility for F2 and F3 fibrosis and prognostication ability—at least in Pi*ZZ carriers—and availability, a potential strategy for liver disease follow‐up in Pi*Z‐related liver disease could consist of the conjunctive use of these NITs with periodic VCTE‐LSM according to the Delphi consensus depending on regional availability (Figure 3).